FDA Approves Updated COVID-19 Vaccines with Limited Use
On Wednesday, U.S. regulators granted approval for updated COVID-19 vaccines, but the scope of who can receive them has been significantly narrowed. Notably, one of the options for young children has been eliminated.
This change seems to arise from data on safety and effectiveness. Regulators feel the vaccines provide the most benefit to specific age groups or high-risk individuals, suggesting that for others, especially young children, the risks or limited benefits could outweigh the positives.
The aim appears to be about focusing on those who will gain the most advantage, while reducing unnecessary exposure for lower-risk groups.
The newly authorized vaccines from Pfizer, Moderna, and Novavax are now available for all seniors. For younger adults and children, however, the FDA has restricted eligibility to those with at least one high-risk health condition, such as asthma or obesity.
A spokesperson from Novavax indicated that its vaccine is expected to be available in early fall.
Importantly, Pfizer’s vaccine can no longer be administered to children under five, as the FDA has revoked its emergency use authorization for that age group. But for parents keen on vaccinations, Moderna’s mRNA vaccine, Spikevax, is still approved for children as young as six months. For Pfizer, the usage now only applies to kids with serious health issues.
FDA representatives mentioned that the updated vaccines, which target a newer variant of the ongoing virus, are anticipated to start shipping soon. However, it might take days or weeks before individuals know if they can access a dose, as this hinges on decisions by federal health advisors, insurers, and local authorities.
This new distribution framework, first outlined by the FDA in May, marks a significant shift from the previous U.S. guideline that recommended annual COVID-19 mRNA vaccinations for everyone aged six months and older.
“The American people demanded science, safety, and common sense. This framework delivers all three,” remarked Health Secretary Robert F. Kennedy Jr. on social media.
Novavax’s COVID-19 vaccine is approved solely for individuals aged 12 and older, with similar risk-based restrictions applied as with Moderna and Pfizer. It remains the only traditional, protein-based COVID-19 vaccine available in the country.
Some medical groups, like the American Academy of Pediatrics, have voiced concerns about the restrictions, suggesting they may “limit access” for families wanting to “protect their children.”
In a statement, Kennedy Jr. stressed that vaccines will be available for anyone wanting them after consulting with their healthcare providers. Typically, insurers decide vaccine coverage based on CDC advisory panel recommendations, though they may also consider input from professional groups like the American Medical Association.
Earlier this year, Kennedy Jr. influenced the CDC advisory panel by introducing more critical voices, emphasizing vaccine safety concerns. He often positions himself as a “critical thinker” in vaccine discussions, at times contradicting the prevailing scientific consensus, which he claims is affected by conflicts of interest.
The advisory panel is scheduled to convene in September, but no plans have been disclosed yet.
So far, Pfizer has not pursued full approval for its vaccines for children under five, leaving Moderna as the only provider for that demographic this year.
On Wednesday, it was announced that not only has the emergency use authorization for Pfizer’s vaccine in young children been revoked, but all remaining authorizations for pandemic-era vaccines have been withdrawn, including convalescent plasma, a treatment once standard for hospitalized patients before antiviral therapies became available.
